<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555944</url>
  </required_header>
  <id_info>
    <org_study_id>MyCard</org_study_id>
    <nct_id>NCT01555944</nct_id>
  </id_info>
  <brief_title>Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines</brief_title>
  <official_title>Screening and Management of Cardiovascular Risk in Belgian Women Aged &gt; or = 65 Years With Metastatic Breast Cancer Before and After Anthracycline Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, multicentre, prospective observational (non-interventional) study, performed&#xD;
      in Belgium.&#xD;
&#xD;
      Principal objectives:&#xD;
&#xD;
        1. To evaluate the prevalence of cardiovascular risk factors and cardiac function (as&#xD;
           routinely evaluated) before treatment with anthracyclines of patients with metastatic&#xD;
           breast cancer (MBC) aged &gt; or = 65 years&#xD;
&#xD;
        2. To observe the management of cardiovascular risk during and after anthracycline&#xD;
           treatment&#xD;
&#xD;
        3. To compare liposomal versus non-liposomal anthracycline therapy (ratio 1:1) on cardiac&#xD;
           function, outcome and quality of life (EORTC QLQ-C30)&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To evaluate the efficacy of anthracyclines on progression free survival and tumor&#xD;
           response as routinely measured (e.g. recist criteria, tumor markers and other exams)&#xD;
&#xD;
        2. To evaluate cardiovascular event type: ECG changes, arrhythmia, decrease of ejection&#xD;
           fraction, heart failure and rate according to allocated treatment.&#xD;
&#xD;
        3. To find out how quality of life, e.g. such as described according to EORTC QLQ-C30&#xD;
           criteria or Karnofsky index is achieved in the various patient subgroups&#xD;
&#xD;
        4. To correlate the therapeutic choice and posology of anthracyclines for MBC with&#xD;
           Cardiovascular risk at baseline&#xD;
&#xD;
        5. To calculate the cardiovascular risk according to SCORE&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The physician will be requested:&#xD;
&#xD;
        -  To include 15 consecutive patients aged &gt; or = 65 years who will be treated with&#xD;
           anthracyclines in first and second line MBC. The physician will be encouraged to enrol 2&#xD;
           arms of 8 patients (one treated with liposomal and one with non-liposomal&#xD;
           anthracyclines) for observation and comparison. Each arm will be closed as soon as 150&#xD;
           patients are included at a national level.&#xD;
&#xD;
        -  To report their cardiovascular risk factors&#xD;
&#xD;
        -  To provide the results of routinely performed cardiac evaluation before treatment&#xD;
&#xD;
        -  To monitor routinely cardiovascular parameters during treatment and report them&#xD;
           afterwards&#xD;
&#xD;
        -  To monitor efficacy and tolerance of treatments, as normal practice prescribes, reported&#xD;
           and related to the variables described in objectives&#xD;
&#xD;
        -  To ensure that quality of life will be assessed with the EORTC QLQ-C30 questionnaire&#xD;
&#xD;
        -  To monitor and report progression free survival and cardiac events&#xD;
&#xD;
        -  To record and transmit spontaneously reported adverse events. These will be handled&#xD;
           according to legal requirements&#xD;
&#xD;
      Follow-up will cover a period of 15 months following inclusion.&#xD;
&#xD;
      The study will have 3 visits and 2 contacts:&#xD;
&#xD;
        -  One visit at entry&#xD;
&#xD;
        -  One visit after 3 cycles of anthracycline containing therapy&#xD;
&#xD;
        -  One visit at the end of treatment&#xD;
&#xD;
        -  Contact at 9 months after inclusion&#xD;
&#xD;
        -  Contact at 15 months after inclusion&#xD;
&#xD;
      It is planned to include data from 15 consecutive female patients per specialized center in&#xD;
      Belgium.&#xD;
&#xD;
      The total number of patients aimed is 300.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular risk factors</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Belgian women aged &gt; or = 65 years with metastatic breast cancer before and after&#xD;
        anthracycline treatment.&#xD;
&#xD;
        Patients will be included in 24 centers specialized in the treatment of breast cancer, in&#xD;
        Belgium.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women aged 65 years old or more&#xD;
&#xD;
          -  with confirmed metastatic breast cancer (MBC)&#xD;
&#xD;
          -  who will be treated with anthracyclines in first or second line&#xD;
&#xD;
          -  who have a Karnofsky score at baseline of 50&#xD;
&#xD;
          -  who agree and are able to fill in the EORTC QLQ-C30 questionnaire&#xD;
&#xD;
          -  who gave their informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women having contra-Indications for anthracyclines&#xD;
&#xD;
          -  women aged &lt; 65 years old&#xD;
&#xD;
          -  with no metastatic breast cancer&#xD;
&#xD;
          -  who will not be eligible for an anthracycline treatment in first or second line MBC&#xD;
&#xD;
          -  who have a Karnofsky less than 50&#xD;
&#xD;
          -  who disagree or are unable to fill in the EORTC QLQ-C30 questionnaire&#xD;
&#xD;
          -  women refusing or not having signed their informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christel Fontaine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques du Sud Lux - St Joseph</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Luc</name>
      <address>
        <city>Bouge</city>
        <zip>5004</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ KLINA</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHIREC - Centre Hospitalier Interr√©gional Edith Cavell</name>
      <address>
        <city>Brussels</city>
        <zip>1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSF</name>
      <address>
        <city>Chimay</city>
        <zip>6460</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St-Maarten</name>
      <address>
        <city>Duffel</city>
        <zip>2570</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St-Dimpna</name>
      <address>
        <city>Geel</city>
        <zip>2440</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St-Lucas</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Jan Palfijn</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMSE</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St Pierre</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>St-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Wallonie picarde - site IMC</name>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHPLT</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <last_update_submitted>April 22, 2016</last_update_submitted>
  <last_update_submitted_qc>April 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 23, 2017</submitted>
    <returned>May 9, 2017</returned>
    <submitted>November 7, 2018</submitted>
    <returned>March 6, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

